MedPath

Teneligliptin effects on DPP-4 and glucagon concentrations in the serum during a meal test in patients with type 2 diabetes

Not Applicable
Recruiting
Conditions
Type 2 diabetes
Registration Number
JPRN-UMIN000012508
Lead Sponsor
Department of Endocrinology and Metabolism,Dokkyo Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients who have type 1 diabetes and/or secondary diabetes (Cushing syndrome or acromegaly). 2.Contraindication for DPP-4 inhibitors 3.Patients who have heart failure (NYHA category 3-4) 4.Patients who are prone to QT prolongation. 5 Alcohol intake excess. 6.Patients who are pregnant or may be pregnant 7.History of myocardial infarction 8.Patients who have received GLP-1 receptor agonists

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Postprandial serum soluble CD26/DPP-4 levels, DPP-4 activity, and plasma glucose
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath